AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q92292

U.S. Application No.: 10/564,722

REMARKS

The present invention relates to a specific composition, as defined in claim 1, discussed

in more detail below.

In the Advisory Action dated July 6, 2007 issued with respect to Applicant's Response

Under 37 C.F.R. § 1.116 filed June 28, 2007, the Examiner indicated checking Box 7 that the

proposed amendments would not be entered and Box 11 that the request for reconsideration had

been considered but did not place the application in condition for allowance, and on the

continuation sheet the Examiner indicated that Applicant's arguments distinguishing over the

curable emulsion of Hasegawa et al failed, in that he claims as written do not require the

components A, B, and C as separate polymers or ingredients, and the Examiner indicated that in

the claim as written components A, B, and C could be interpreted as the components of a

polymeric composition.

In the present Amendment, independent claim 1 has been amended to improve the clarity

of the claims, responsive to the Examiner's comments, by reciting that the curable composition

in accordance with the present invention comprises "a mixture of" the components (A), (B), and

(C).

6

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q92292

U.S. Application No.: 10/564,722

The amendment of claim 1 is supported, for example, by Synthesis Example 2 (mixing of (A) and (B)) and Examples 1 - 5 (mixing of (C) and the above mixture of (A) and (B)) in the

specification.

Accordingly, in view of the amendment of claim 1 herein, it is respectfully submitted that

all of claims 1 - 20 now clearly distinguish over the Hasegawa et al reference, and the rejections

under 35 U.S.C. §102 and 35 U.S.C. §103, both of which are based Hasegawa et al as the

primary reference, should now be withdrawn.

In view of the above, reconsideration and allowance of claims 1 - 20 as they are now

pending in this application are now believed to be in order, and such actions are hereby earnestly

solicited.

If any points remain in issue which the Examiner feels may be best resolved through a

personal or telephone interview, the Examiner is kindly requested to contact the undersigned

attorney at the local Washington, D.C. telephone number listed below.

7

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q92292

U.S. Application No.: 10/564,722

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

foseph of

Registration No. 26.577

SUGHRUE MION, PLLC Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: July 30, 2007